US pharmaceutical company Allergan has entered into a settlement with Indian manufacturer Intas Pharmaceuticals on the use of the trademarks ‘Botox’ and‘BTX-A’ for botulinum toxin.
Global pharmaceutical company Allergan has announced that it has completed the acquisition of Kythera Biopharmaceuticals, Inc in a transaction valued at approximately $2.1 billion.
A study carried out by Dr Alastair Carruthers et al has suggested that, in patients who regularly received Botox treatments for more than five years, the time between treatments increased over 22 treatments for glabellar and crow's feet lines.
The Food and Drugs Administration (FDA) is alerting health professionals to a counterfeit version of Botox that is being distributed in the US.
Botox-maker Allergan has revealed that their fourth-quarter profits have beaten expectations. Reaching $537.2 million, Allergan reported that this was a two million dollar increase on the same period last year, which sat at $312.9 million.
Today Actavis and Allergan confirmed their request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), in regards to the pending acquisition of Allergan by Actavis, has been accepted by the US Federal Trade Commission (FTC).
Global pharmaceutical company Actavis has confirmed that it will acquire Allergan for $66 billion, or $219 per share. The agreement sees Actavis purchase the Botox-maker for a combination of $129.22 in cash and 0.3683 Actavis shares, for each share of Allergan common stock.
The Irish Association of Aesthetic Plastic Surgeons (ISAPS) has warned that the recent conviction of a beautician performing illegal botulinum toxin treatments has highlighted the need for more regulation in the cosmetic arena.
The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has released a statement warning consumers about the risks involved in discounted facial cosmetic procedures.
Pharmaceutical company Allergan has announced the promotion of Caroline Van Hove to vice president and managing director. She will now be responsible for the business performance of Allergan’s facial aesthetics portfolio and breast implant business across Europe, Africa and the Middle East. Previously senior marketing director of facial aesthetics and then medical aesthetics in Europe, the Middle East and Africa (EAME), Allergan says Van Hove was the driving force behind several of their key initiatives.